Pharos IBio Co (XKRX:388870) Accounts Payable & Accrued Expense : ₩914.06 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Pharos IBio Co Accounts Payable & Accrued Expense?

Pharos IBio Co's quarterly accounts payable & accrued expense increased from Sep. 2024 (₩336.13 Mil) to Dec. 2024 (₩642.07 Mil) and increased from Dec. 2024 (₩642.07 Mil) to Mar. 2025 (₩914.06 Mil).

Pharos IBio Co's annual accounts payable & accrued expense increased from Dec. 2022 (₩500.61 Mil) to Dec. 2023 (₩903.72 Mil) but then declined from Dec. 2023 (₩903.72 Mil) to Dec. 2024 (₩642.07 Mil).

Pharos IBio Co Accounts Payable & Accrued Expense Historical Data

The historical data trend for Pharos IBio Co's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharos IBio Co Accounts Payable & Accrued Expense Chart

Pharos IBio Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

592.73

208.34

500.61

903.72

642.07

Pharos IBio Co Quarterly Data
	Dec19	Dec20	Dec21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial										722.02	530.32	336.13	642.07	914.06

Pharos IBio Co Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Pharos IBio Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharos IBio Co Ltd (XKRX:388870) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

427beon-gil, Dongan-gu, 1407 and 1408, 38, Heungan-daero, Seongji Star With, Gyeonggi-do, Gwanyang-dong, Anyang-si, KOR

Website

https://www.pharosibio.com

Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.

Pharos IBio Co Headlines

No Headlines